Corbus Pharmaceuticals updates Phase 1/2 CRB-701 data with 42.9% ORR in 2L oropharyngeal SCC, 34.4% in 2L cervical cancer
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $881.71K | $3.94M | $36.14M | $4.82M | $2.44M |
| Cost of Revenue | $600.00K | N/A | $1.49M | $1.64M | N/A | $89.60M | $48.61M | $26.04M |
| Gross Profit | $-600.00K | N/A | $-1.49M | $-757.53K | $3.94M | $-53.46M | $-43.79M | $-23.60M |
| Gross Margin | 0.00% | 0.00% | 0.00% | -85.92% | 100.00% | -147.91% | -908.11% | -967.09% |
| Operating Expenses | $48.12M | $45.08M | $33.35M | $55.23M | $126.75M | $23.64M | $12.96M | $8.96M |
| Operating Income | $-48.72M | $-45.08M | $-34.84M | $-55.99M | $-122.81M | $-77.10M | $-56.75M | $-32.56M |
| Operating Margin | 0.00% | 0.00% | 0.00% | -6350.09% | -3119.20% | -213.33% | -1176.78% | -1334.43% |
| Net Income | $-40.21M | $-44.60M | $-55.83M | $-45.55M | $-111.27M | $-71.45M | $-55.67M | $-32.42M |
| Net Margin | 0.00% | 0.00% | 0.00% | -5166.42% | -2826.08% | -197.69% | -1154.48% | -1328.65% |
| EPS (Basic) | $-3.68 | $-10.31 | $-10.15 | $-11.11 | $-42.74 | $-32.47 | $-29.30 | $-19.38 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |